Screener
Lexicon Pharmaceuticals LXRX Business Segments — Interest income and other
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001062822-26-000117
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| General and administrative | 6,964 | 6,466 | 13,408 | 14,292 |
| Other segment expense (1) | 3,336 | 3,271 | 6,414 | 6,072 |
| Total operating expenses | 27,232 | 25,130 | 49,330 | 52,071 |
| (Loss) income from operations | (26,540) | 3,736 | (27,536) | (21,943) |
| Interest and other expense | (2,609) | (2,318) | (4,199) | (4,153) |
| Interest and other income | 1,723 | 1,834 | 3,266 | 4,053 |
| Loss on early extinguishment of debt | (4,349) | — | (4,349) | — |
| Net (loss) income | $(31,775) | $3,252 | $(32,818) | $(22,043) |
Item 1. Financial Statements
FAQ
- What is Lexicon Pharmaceuticals's business segments — interest income and other?
- Lexicon Pharmaceuticals (LXRX) reported business segments — interest income and other of $1.72M in Q2 2026.
- How has Lexicon Pharmaceuticals's business segments — interest income and other changed year-over-year?
- Lexicon Pharmaceuticals's business segments — interest income and other decreased by 6.1% year-over-year, from $1.83M to $1.72M.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — interest income and other?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — interest income and other has grown at a 63.0% compound annual growth rate (CAGR), from $1.6M to $6.91M.
- What does business segments — interest income and other mean?
- This metric represents the non-operating income generated by a specific business segment, primarily derived from cash equivalents, short-term investments, and other miscellaneous financial activities. It reflects the segment's ability to generate supplemental yield from its allocated capital base. Monitoring this helps investors assess the efficiency of cash management within the segment's operations.
Ask your AI about Lexicon Pharmaceuticals's business segments — interest income and other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude